Spots Global Cancer Trial Database for Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors
Official Title: A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL765 Administered Orally Daily to Subjects With Solid Tumors
Study ID: NCT00485719
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the safety and tolerability of XL765. XL765 is a new chemical entity that inhibits the kinases PI3K and mTOR. In preclinical studies, inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells, whereas inactivation of mTOR has been shown to inhibit the growth of tumor cells.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Investigational Site Number 1302, Detroit, Michigan, United States
Investigational Site Number 1435, Omaha, Nebraska, United States
Investigational Site Number 1402, San Antonio, Texas, United States
Investigational Site Number 3411, Barcelona, , Spain
Contact Details
Name: Clinical Sciences & Operations
Affiliation: Sanofi
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
